HHC
IART icon

Hutchin Hill Capital’s Integra LifeSciences IART Stock Holding History

Hutchin Hill Capital’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-17,200
Closed -$738K – 944
2016
Q4 		$738K Buy
+17,200
New +$699K 0.03% 518

Other funds holding IART

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hutchin Hill Capital's IART Position: Q1 2017 in Review

Hutchin Hill Capital sold out of Integra LifeSciences (IART) in Q1 2017, closing a stake of 17,200 shares — an estimated $738K sold.

Hutchin Hill Capital first reported a position in IART in Q4 2016 and held it in 1 quarter. The position peaked at $738K in Q4 2016. 236 funds tracked by Wall St. Rank hold IART as of Q1 2017.

  • Hutchin Hill Capital reported no remaining Integra LifeSciences position as of Q1 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 17,200 Integra LifeSciences shares in Q1 2017, an estimated $738K.
  • Hutchin Hill Capital first reported a position in Integra LifeSciences in Q4 2016 and held it in 1 quarter.
  • Hutchin Hill Capital's Integra LifeSciences position peaked at $738K in Q4 2016.
  • 236 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2017.

Based on Hutchin Hill Capital's 13F filing for Q1 2017, filed 15 May 2017.